children and adolescents undergoing PSF. The secondary objective was to combine PK data from older children and adolescents in this study with PK data from a cohort of infants in a previous study to provide dosing guidance to achieve target concentrations across a range of ages, diagnoses, and weights.
Methods

Clinical trial
This analysis includes data from both a prospective PK trial in children ages 8-18 years undergoing PSF for idiopathic and non-idiopathic scoliosis and previously reported data from an open-label, non-randomised, dose escalation PK trial in infants ages 2-24 months undergoing craniofacial surgery. 15 The adolescent scoliosis study was a single-centre, prospective PK study conducted in subjects undergoing PSF (http://www.clinicaltrials.gov; NCT01408823). The study was conducted following institutional review board approval and written informed consent and subject assent. Males and females ages 8-18 years undergoing PSF surgery for scoliosis for whom EACA administration was planned as part of standard care by the anaesthesiology team were eligible for enrolment. Subjects who did not have a parent or legal guardian who spoke English and subjects with a history of abnormal renal function were excluded. An evaluable subject was defined as any enrolled subject who had at least seven PK blood samples drawn and was not withdrawn from the study for other reasons. After eligibility was verified and informed consent and assent (when appropriate) were obtained, subjects were assigned to one of two groups based on their diagnosed scoliosis aetiology: an idiopathic scoliosis group and a non-idiopathic scoliosis group. Subjects were enrolled until there were 10 evaluable subjects in each of the two study groups (total of 20 subjects).
Details regarding trial conduct for the craniofacial study were previously reported. 15 Briefly, this was a dose-escalating trial involving 18 subjects divided into three cohorts of six infants. The first cohort received a 25 mg kg 21 
Administration of EACA
In the PSF trial, EACA dosing was determined by our local institutional practice, which is based on the regimen reported in adolescents undergoing spinal fusion: a 100 mg kg 21 loading dose followed by a CIVI of 10 mg kg 21 h 21 .
2 -4 7 8 EACA administration began in the operating room following induction of anaesthesia after vascular access was obtained. The EACA loading dose was administered over 10 min using a programmed infusion pump and was followed by the CIVI until skin closure. In one subject the anaesthesiologist limited the maximum loading dose to 5 g of EACA (for a total of 80 mg kg 21 as a loading dose). Patient information and data pertaining to the medical management and perioperative course of enrolled subjects were collected, including age, weight, gender, diagnosis, surgical procedure, duration of surgery, and estimated blood loss.
Conduct of anaesthesia
All subjects received general tracheal anaesthesia with standard American Society of Anesthesiologists monitoring. Mask induction of anaesthesia was performed with sevoflurane, nitrous oxide, and oxygen. To facilitate intraoperative monitoring of somatosensory evoked potentials and transcranial electric motor evoked potentials, anaesthesia was maintained with intravenous (i.v.) infusions of propofol, an opioid (remifentanil or fentanyl), and in some subjects, ketamine. Additional parenteral opioids (fentanyl, hydromorphone, morphine, methadone) were administered for anaesthetic supplementation and postoperative analgesia. Each subject had two peripheral i.v. catheters and a radial arterial catheter placed as part of standard management. In six cases a central venous catheter was inserted at the discretion of the anaesthesiologist; all of these were in the non-idiopathic group. Maintenance of normothermia was facilitated using forced air convection blanket warmers and an i.v. fluid warmer. Anaesthetic management, fluid management, and blood loss replacement were at the discretion of anaesthesia providers without a fixed protocol.
PK sampling
For the subjects undergoing PSF surgery, PK samples (1 ml of blood) were drawn immediately before and after the loading dose, after initiation of CIVI (0.5, 2, 3, and 4 h), at the end of CIVI, and following the end of CIVI (0.5, 2, 4, and 6 h), for a maximum of 11 PK samples per subject. Intraoperative PK samples were drawn from the arterial catheter. During the postoperative period, blood was drawn from the arterial catheter when present, or from a blood-drawing i.v. catheter. If neither was present, samples were drawn together with routine postoperative laboratory blood draws and the time of phlebotomy was recorded. Blood samples were collected in Microtainer tubes (BD, Franklin Lakes, NJ, USA) containing lithium heparin and stored at 48C for up to 12 h prior to centrifugation and separation of plasma. Samples were centrifuged at 3500 rpm at 48C for 15 min. Plasma was separated and stored at 2808C. Details regarding PK sampling in the craniofacial population are described in our previous publication. 15 
Drug quantitation
A selective and highly sensitive method for the determination of EACA in human plasma was developed and fully validated based on high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS). Sample preparation involved dilution with 10% acetic acid and addition of the internal standard aminoheptanoic acid. To 50 ml of each plasma sample, 1.0 ml of 10% acetic acid in water was added. After vortexing, a 50 ml aliquot of the diluted sample was transferred and mixed with 50 ml of internal standard working solution (2 mg ml 21 ) and 5 ml of water, and 300 ml of each sample was transferred to a 96-well plate and centrifuged at 3500 rpm for 10 min. 
Pharmacostatistical analysis
Model building
The population PK analysis was conducted using non-linear mixed effects methods (NONMEM software, ICON Development Solutions, Ellicott City, MD, USA, version VI, level 2.0 with subroutines ADVAN 3, TRANS 4). All models were run with the first-order conditional estimation with interaction (FOCE-I) method. S-Plus version 6.2 (Insightful, Data Analysis Products Division, Seattle, WA, USA) was used for goodnessof-fit diagnostics and graphical displays. The goodness-of-fit from each model run was assessed by examination of the following criteria: diagnostic plots; standard errors of the parameters; global minimization of the search algorithm; the Akaike Information Criterion, which is equal to the minimum objective function value (MOFV) plus two times the number of parameters; and plausibility of parameter estimates.
Base model
One-and two-compartment models were investigated. A twocompartment disposition model was selected to define the EACA plasma concentration profile based on results from the model-building process and previously published data. 9 11 Models were parameterized by clearance (Cl, ml min 21 ), intercompartmental clearance (Q, ml min 21 ), central volume of distribution (V1, litres), and peripheral volume of distribution (V2, litres). The one-compartment model was inadequate to describe the data. An exponential variance model was used to describe the variability of PK parameters across individuals in the form P i ¼u k exp(h ki ), where P i is the estimated parameter value for the individual subject i, u k is the typical population value of parameter k, and h ki is the interindividual random effects for individual i and parameter k. Interindividual variability was initially estimated for clearance and then subsequently for the remaining PK parameters.
Additive, proportional, and combined (additive and proportional) residual error models were considered during the model-building process. Ultimately a combined additive and proportional error model was used to describe random residual variability: C obs,ij ¼(C pred,ij *(1+1 ijP ))+1 ijA , where C obs,ij is the observed concentration j in individual i, C pred,ij is the individual predicted concentration, 1 ijP is the proportional residual random error, and 1 ijA is the additive residual random error for individual i and measurement j.
The impact of weight on all parameters was implemented using an allometric model:
where TVP is the typical value of a model parameter, described as a function of body weight, u TVP is an estimated parameter describing the typical PK parameter value for an individual with weight equal to the reference weight, WT i is body weight, WT ref is the reference value (70 kg for this analysis), and u allometric is an allometric power parameter based on physiologic consideration of size on metabolic processes, fixed at 0.75 for clearances and at 1 for volumes. 16 17 Full covariate model A full covariate model was constructed in order to make inferences about effects of covariates on EACA disposition. Covariate effects were predefined based on clinical interest, prior knowledge, and physiologic plausibility. The analysis was focused on estimation of effects and avoided the problem of selection bias, which is particularly problematic with stepwise model building in small data sets. 18 19 The effects of age and diagnosis were evaluated in this model. Blood loss was not evaluated in the model because it was not measured in a timedependent fashion, did not account for administration of blood products, and was correlated with diagnosis.
Dosing guidance
Once estimates of Cl were obtained via the model-building process, the steady-state concentrations (C ss ) that would be achieved with a linearly scaled weight-based dosing strategy were simulated across a range of weights, assuming full Cl maturation, using the equation
Cl (litre h −1 ) .
The estimated random intersubject variability for Cl was used to calculate a 95% population prediction interval for Cl for a specific weight (WT), using the equations 20 21 additional dosing schemes were evaluated in each population to determine the dose that would achieve a C ss .130 mg ml 21 in .97.5% of subjects, using estimates of interindividual variability.
Results
Study conduct
For the PSF population, 45 patients were screened for enrolment. Of these, 23 were eligible for the study and 21 were approached for enrolment. Of these, 20 subjects were enrolled in the study, all of whom were evaluable and subsequently included in the PK analysis. Diagnoses of evaluable PSF subjects are presented in Table 1 . Diagnoses for infants undergoing craniofacial surgery are described in our previous publication 15 but are presented in Table 2 for comparison. A summary of PK study variables for all study groups is presented in Table 3 . The craniofacial population was younger, weighed less, had a higher percentage of PK samples drawn in the postoperative period as opposed to the intraoperative period, and had the shortest duration of surgery. Our previous analysis of the craniofacial population indicated that intraoperative EACA Cl was less than the postoperative Cl. This analysis was possible in the craniofacial population because PK sampling occurred almost equally intraoperatively and postoperatively. Since the majority of PK samples in the PSF population occurred in the intraoperative setting (where Cl is reduced based on the previous analysis), we anticipated that a combined model would result in an underestimate of population Cl. Therefore diagnosis was evaluated as a covariate in the combined model that included the craniofacial and PSF populations. In addition, we did not compare intraoperative and postoperative clearances in the PSF population since there were so few postoperative samples. 
PK modelling and simulation
Semi-log plots of EACA concentration -time profiles for the three study groups are presented in Figure 1 . Most doses resulted in steady-state concentrations during the operative procedure lower than the target of 130 mg ml 21 . This was not seen in the highest dosing cohort of craniofacial children, who received a larger dose (100 mg kg 21 loading dose followed by CIVI of 40 mg kg 21 h 21 ).
The final structural model was a two-compartment disposition model with interindividual random effects estimated on Cl, V1 and V2. Using FOCE-I estimation, the base model minimized with successful execution of the covariance matrix of the estimates. Scaling the PK parameters allometrically to weight resulted in a 153-point improvement in the minimum value of the objective function (MVOF) compared with a model without weight. The addition of an interindividual variability estimate on Q resulted in less precise parameter estimates (the SE on the Cl estimate increased from 6.99 to 34.24) and poor model stability, and therefore was not included in the final model. The full covariate model was developed by simultaneously including effects for covariates of clinical interest and those with physiologic plausibility. Despite no improvement with the MOFV, age and diagnosis were included in the final model to estimate the magnitude and precision of these effects on Cl. As part of model building, the impact of the correlation of age and surgery type on the parameter effect estimates of age were evaluated, and this parameter was unchanged with or without the inclusion of surgery type. Given the full covariate model, the impact of potential correlation in covariates was evaluated. Univariate exclusion of concomitant predictors had little to no impact on the point estimates of other covariates, indicating that the model provided unique information about each predictor.
The model for the age-related maturational effect on Cl was implemented as an asymptotically increasing maximum effect model. The model-estimated age at which 50% of full Cl was achieved was 1.53 months (54.7% SE). Given this point estimate, however, it is expected that 90% of full maturation Cl should occur at approximately 15 months. The model predicted a 10% increase in Cl for idiopathic PSF and a 3% reduction in Cl for non-idiopathic PSF as compared with the craniofacial group, neither of which is clinically relevant.
Observed vs population and individual predicted values revealed no systematic bias in the prediction of plasma concentrations for the entire study (Fig. 2) . Modelling progression is represented in Table 4 . Age was a covariate of interest, and the age effect on clearance was included in the final model. However, given the small change in the MVOF, a model without age effect is also included. Parameter estimates for both models are represented in Table 5 .
Dosing guidance
The population value for Cl was 153 ml min 21 (Table 6 ). This is graphically represented in Figure 3 . Weight-based dosing strategies that would result in a C ss above the 97.5th prediction interval are presented in Table 7 . Dosing strategies for patients ,6 months of age are not provided, as the youngest child in this cohort was 6.7 months. Based on the population model, children weighing 7. Figure 4 . This simulation represents the best estimate of the range of concentrations using the specified dosing regimens without including the precision estimate of interindividual variability. The current dosing scheme (100 mg kg 21 load, 10 mg kg 21 h 21 CIVI) used in the scoliosis population does not result in concentrations .130 mcg ml 21 in any cohort once steady state is obtained. The large bolus dose:infusion dose ratio (10:1) provides higher concentrations initially, however, these concentrations cannot be maintained with a low CIVI dose. The minimal difference in the Cl parameter estimates for the idiopathic and non-idiopathic scoliosis subjects is demonstrated in the simulations (Fig. 4) , where the simulated concentrations in the non-idiopathic group are almost identical to those in the idiopathic group using the same dosing regimen.
Discussion
Population PK parameters for EACA were estimated using a two-compartment disposition model with allometrically scaled weight and an age effect on clearance. Note that the scoliosis population received a bolus of 100 mg kg 21 followed by a CIVI Pre-bolus concentrations are omitted (all less than the lower limit of quantitation). Plasma concentrations obtained prior to and after end of infusion (time 0) are shown. surgery) or of PSF study group (idiopathic compared with nonidiopathic) on drug Cl. Many biologic characteristics are described using allometric scaling, where the observed characteristic exhibits a logarithmic relationship with weight or size rather than a linear relationship. As a result of this logarithmic relationship in the PKs of EACA, if linear dosing is used, a 15 kg difference in weight in children (e.g. 25 kg vs 10 kg) will have a disproportionately higher effect on drug concentrations compared with the same 15 kg difference in an adult (e.g. 85 kg vs 70 kg). Consequently, interpolating paediatric dosing from adult dosing in a linear fashion based on weight is problematic and often results in subtherapeutic or supratherapeutic drug concentrations. This was seen in Figure 3 , where a fixed dosing strategy results in a lower C ss for a 10 kg patient vs a 50 kg patient.
The therapeutic plasma concentration of EACA to control systemic fibrinolytic activity was determined to be 130 mcg mL
21
; dosing strategies based on PK studies in adults 10 12 and children 22 have been targeted to maintain plasma EACA levels of ≥130 mg litre 21 (1 mM). 20 21 This target plasma concentration of EACA is based on in vitro data where the therapeutic concentration is the concentration that completely inhibits fibrinolysis caused by supraphysiologic plasminogen activation. There is currently no suitable pharmacodynamic indicator for determining target EACA concentrations for blood loss reduction in non-cardiac surgery. In a study evaluating the antifibrinolytic tranexamic acid in craniofacial surgery, efficacy in reducing blood loss was demonstrated without a detectable effect on fibrinolytic activity on thromboelastography for tranexamic acid. 23 Given the absence of EACA dose or concentration range efficacy data in this population, therapeutic targets remain based on in vitro data. 24 The evidence for adverse effects of slight overdosing of EACA is sparse. Going forth, a trial to determine the minimal concentration for efficacy as well as whether a larger concentration might prove more efficacious is needed. 
Limitations
Although sample size was a potential limitation of this study, the structural PK parameters were precisely estimated.
Previous PK studies of EACA in adults have included 6 subjects, 11 10 subjects, 25 and 16 subjects. 26 PK studies in children involved 9 subjects 22 and 18 subjects. 15 Another limitation was that there were fewer postoperative PK samples collected. However, initial postoperative samples (0.5 and 2 h following the end of the CIVI) were collected in nearly all subjects, and all potential intraoperative samples were drawn in all subjects. The current study did not provide reliable information about the effects of age. Although the estimate of age effect was imprecise, it was included in the final model since it represents a clinically relevant covariate.
Conclusions
EACA PK behaviour is influenced by weight, age and perioperative conditions (intraoperative compared with postoperative time period). Weight-based dosing in this population is appropriate, and based on modelling from this study, the following dosing schemes are recommended to maintain target plasma EACA concentrations: weight ,25 kg, 100 mg kg 
